Science in Dyslipidaemia Disease Management

Get a 360º view and stay up-to-date on dyslipidaemia disease with content selected for you.

Prescribing Information can be found through the links in the Product Cards at the bottom of the page.

ODYSSEY OUTCOMES | Trial Design | Praluent® (alirocumab)

ODYSSEY OUTCOMES |Efficacy | Praluent® (alirocumab)

ODYSSEY OUTCOMES | Safety Profile | Praluent® (alirocumab)

OUTCOMES IN DIABETES PATIENTS | Praluent® (alirocumab)

FH I & FH II Studies | Praluent® (alirocumab)
SEE ALL

Resources

Resources created to help you in your clinical practice and improve the quality of life of your patients

Unmet Needs in Dyslipidaemia

Specific Characteristics of Praluent | Praluent® (alirocumab)

NICE and SMC Guidance | Praluent® (alirocumab)

Dyslipidaemia guidelines interactive tool
SEE ALL

What the experts think

Residual risk in the ACS patient and the contribution of cholesterol

Why use Praluent® (alirocumab) in patients with ACS?

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES - Randomised Clinical Trial.

 †With only nominal statistical significance by hierarchical testing (HR 0.85, 95% CI 0.73, 0.98)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.

Get in touch with the Dyslipidaemia Team

MAT-XU-2201545 (v3.0)
Date of Preparation: February 2023

Dyslipidaemia Product

Praluent
alirocumab

Prescribing Information GB
Prescribing Information NI

 

MAT-XU-2204604 (v1.0)
Date of preparation: October 2022

MAT-XU-2204598 (v2.0)  
Date of Preparation: March 2023